Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Glacier Oncology, PLLC
mi
from
Kalispell, MT
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Glacier Oncology, PLLC
mi
from
Kalispell, MT
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Kalispell Medical Oncology at KRMC
mi
from
Kalispell, MT
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Kalispell Medical Oncology at KRMC
mi
from
Kalispell, MT
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Kalispell Regional Medical Center
mi
from
Kalispell, MT
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Kalispell Regional Medical Center
mi
from
Kalispell, MT
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Community Medical Center
mi
from
Missoula, MT
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Community Medical Center
mi
from
Missoula, MT
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Guardian Oncology and Center for Wellness
mi
from
Missoula, MT
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Guardian Oncology and Center for Wellness
mi
from
Missoula, MT
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Montana Cancer Specialists at Montana Cancer Center
mi
from
Missoula, MT
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Montana Cancer Specialists at Montana Cancer Center
mi
from
Missoula, MT
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Montana Cancer Center
mi
from
Missoula, MT
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Montana Cancer Center
mi
from
Missoula, MT
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Immanuel Medical Center
mi
from
Omaha, NE
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Immanuel Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Alegent Health Cancer Center at Bergan Mercy Medical Center
mi
from
Omaha, NE
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Alegent Health Cancer Center at Bergan Mercy Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Creighton University Medical Center
mi
from
Omaha, NE
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Creighton University Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Bismarck Cancer Center
mi
from
Bismarck, ND
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Bismarck Cancer Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Medcenter One Hospital Cancer Care Center
mi
from
Bismarck, ND
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Medcenter One Hospital Cancer Care Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mid Dakota Clinic, PC
mi
from
Bismarck, ND
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mid Dakota Clinic, PC
mi
from
Bismarck, ND
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
St. Alexius Medical Center Cancer Center
mi
from
Bismarck, ND
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
St. Alexius Medical Center Cancer Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
CCOP - MeritCare Hospital
mi
from
Fargo, ND
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
CCOP - MeritCare Hospital
mi
from
Fargo, ND
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Sanford Broadway Clinic
mi
from
Fargo, ND
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Sanford Broadway Clinic
mi
from
Fargo, ND
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mary Rutan Hospital
mi
from
Bellefontaine, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mary Rutan Hospital
mi
from
Bellefontaine, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Wood County Oncology Center
mi
from
Bowling Green, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Wood County Oncology Center
mi
from
Bowling Green, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Adena Regional Medical Center
mi
from
Chillicothe, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Adena Regional Medical Center
mi
from
Chillicothe, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Riverside Methodist Hospital Cancer Care
mi
from
Columbus, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Riverside Methodist Hospital Cancer Care
mi
from
Columbus, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
CCOP - Columbus
mi
from
Columbus, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
CCOP - Columbus
mi
from
Columbus, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Grant Medical Center Cancer Care
mi
from
Columbus, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Grant Medical Center Cancer Care
mi
from
Columbus, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mount Carmel West Hospital
mi
from
Columbus, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mount Carmel West Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Doctors Hospital at Ohio Health
mi
from
Columbus, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Doctors Hospital at Ohio Health
mi
from
Columbus, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Grandview Hospital
mi
from
Dayton, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Grandview Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital
mi
from
Dayton, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Samaritan North Cancer Care Center
mi
from
Dayton, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Samaritan North Cancer Care Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Veterans Affairs Medical Center - Dayton
mi
from
Dayton, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Veterans Affairs Medical Center - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
CCOP - Dayton
mi
from
Dayton, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Grady Memorial Hospital
mi
from
Delaware, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Grady Memorial Hospital
mi
from
Delaware, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Blanchard Valley Medical Associates
mi
from
Findlay, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Blanchard Valley Medical Associates
mi
from
Findlay, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Middletown Regional Hospital
mi
from
Franklin, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Middletown Regional Hospital
mi
from
Franklin, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Fairfield Medical Center
mi
from
Lancaster, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Fairfield Medical Center
mi
from
Lancaster, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Lima Memorial Hospital
mi
from
Lima, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Lima Memorial Hospital
mi
from
Lima, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Strecker Cancer Center at Marietta Memorial Hospital
mi
from
Marietta, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Strecker Cancer Center at Marietta Memorial Hospital
mi
from
Marietta, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Northwest Ohio Oncology Center
mi
from
Maumee, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Northwest Ohio Oncology Center
mi
from
Maumee, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
St. Luke's Hospital
mi
from
Maumee, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
St. Luke's Hospital
mi
from
Maumee, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Licking Memorial Cancer Care Program at Licking Memorial Hospital
mi
from
Newark, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Licking Memorial Cancer Care Program at Licking Memorial Hospital
mi
from
Newark, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
St. Charles Mercy Hospital
mi
from
Oregon, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
St. Charles Mercy Hospital
mi
from
Oregon, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Toledo Clinic - Oregon
mi
from
Oregon, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Toledo Clinic - Oregon
mi
from
Oregon, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Firelands Regional Medical Center
mi
from
Sandusky, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Firelands Regional Medical Center
mi
from
Sandusky, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mercy Medical Center
mi
from
Springfield, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mercy Medical Center
mi
from
Springfield, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Community Hospital of Springfield and Clark County
mi
from
Springfield, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Community Hospital of Springfield and Clark County
mi
from
Springfield, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Flower Hospital Cancer Center
mi
from
Sylvania, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Flower Hospital Cancer Center
mi
from
Sylvania, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Toledo Hospital
mi
from
Toledo, OH
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Toledo Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials